上海交通大学学报(医学版) ›› 2021, Vol. 41 ›› Issue (8): 1114-1119.doi: 10.3969/j.issn.1674-8115.2021.08.020

• 综述 • 上一篇    下一篇

非小细胞肺癌免疫治疗获益人群筛选的研究进展

凌徐心仪(), 张瑶(), 钟华()   

  1. 上海交通大学附属胸科医院呼吸内科,上海 200030
  • 出版日期:2021-08-28 发布日期:2021-08-13
  • 通讯作者: 钟华 E-mail:karen_lxxy@sjtu.edu.cn;eddiedong8@hotmail.com
  • 作者简介:凌徐心仪(1997—),女,博士生;电子信箱:karen_lxxy@sjtu.edu.cn
    凌徐心仪(1997—),女,博士生;电子信箱:karen_lxxy@sjtu.edu.cn
  • 基金资助:
    上海市科学技术委员会2019年度医学引导类(中、西医)科技支撑项目(19411970900)

Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy

Xu-xin-yi LING(), Yao ZHANG(), Hua ZHONG()   

  1. Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
  • Online:2021-08-28 Published:2021-08-13
  • Contact: Hua ZHONG E-mail:karen_lxxy@sjtu.edu.cn;eddiedong8@hotmail.com
  • Supported by:
    Shanghai Medical Guidance;Science and Technology Support Project(19411970900)

摘要:

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)投入临床应用后,非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗步入了全新的时代。但并非所有NSCLC患者都能获益,因此选择合适的生物标志物来预测患者对ICIs的应答水平尤为重要。ICIs作用机制复杂,很多肿瘤免疫反应中涉及的环节(肿瘤相关细胞、分子或基因特征)都可能影响患者对ICIs的应答,因此可用于预测NSCLC患者对ICIs的应答水平。目前已有很多研究在探索现有生物标志物的临床意义与其局限性,并努力发掘潜在的新兴生物标志物,以及联合多重标志物,以期建立更可靠的疗效预测模型。该文基于最新的研究做一综述,归纳目前NSCLC免疫治疗获益人群筛选的生物标志物应用情况与研究进展。

关键词: 非小细胞肺癌, 免疫治疗, 免疫检查点抑制剂, 生物标志物

Abstract:

The application of immune checkpoint inhibitors (ICIs) has brought the treatment of non-small cell lung cancer (NSCLC) into a brand-new age. However, not all patients with NSCLC can benefit from ICIs, and there is currently no good standard for screening the beneficiaries, which provides difficulties for ICIs to bring greater benefits to patients. Therefore, it is quite important to explore suitable biomarkers that can predict the level of patients′ response to ICIs. Due to the complexity of the mechanism of the action of ICIs, many links involved in the tumor immune response, including tumor-related cells, molecules or genetic characteristics, may affect the patients' response to ICIs, and may also have the ability to predict the level of NSCLC patients' response to ICIs at the same time. Currently many studies are exploring the clinical significance and limitations of existing biomarkers, struggling to explore potential emerging biomarkers and combine multiple biomarkers for a more reliable predicting model, in order to bring precise treatment to patients with NSCLC. This article is a review based on the latest research results. It summarizes the current application and research progress of biomarkers to screen NSCLC candidates who will benefit from immunotherapy.

Key words: non-small-cell lung cancer (NSCLC), immunotherapy, immune checkpoint inhibitor (ICI), biomarker

中图分类号: